The Sabrina Kaiser Foundation for Astrocytoma Research is currently in the setup process and expected to be fully operational by July 2025.

The non-profit Foundation is dedicated to improving treatment options for astrocytoma patients and is named after the founder's daughter.

At the age of 26, Sabrina Kaiser was diagnosed with an IDH-mutant grade 2 astrocytoma. In January 2025, the tumor was successfully surgically removed to the level of MRI-undetectability at Heidelberg University Hospital, thus predicting a good prognosis for the coming years.

It is quite likely that one can live to a very old age with this disease – especially with a favorable prognosis. However, part of this prognosis is, that the tumor will most likely return – even multiple times – and then require further surgery, radiation therapy and chemotherapy.

The foundation was established based on the insight that there are currently various therapeutic approaches for astrocytoma treatments that cannot be pursued to the desired extent due to a lack of the necessary budgets and funding.

A focus of these initiatives is currently in the Mannheim-Heidelberg region. For this reason, the foundation is initially focusing its funding activities on a consortium of local working groups in this region only. In a further step, the foundation will also support projects and initiatives outside the Mannheim-Heidelberg region and on an opportunistic basis. In addition, the annual award of a research prize is planned.

If one or more of these approaches are successful, this could make a significant difference for all affected patients in terms of quality of life, time between treatments, and ultimately, life expectancy.
And this would be the ultimate reward for the founder and certainly also for all those who have dedicated their time, inspiration and expertise to improving the treatment options for astrocytomas.